Yesterday Amgen AMGN -1.33% won FDA approval for Imlygic, known until now as T-VEC (talimogene laherparepvec), to treat melanoma that has recurred after surgery. The drug isn’t expected to have a huge impact on the company’s top or bottom line—longtime biotech analyst Eric Schmidt of Cowen & Co. recently estimated it would bring in only about $200 million a year in sales at best. But it’s a notable approval nonetheless, because Imlygic is the first in a brand new class of cancer immunotherapies.
Hey, check out all the research scientist jobs. Post your resume today!
